Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors - Wikidata - awgldk - TriplyDB

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

http://www.wikidata.org/entity/Q36187003

about

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease 'Acute myeloid leukemia: a comprehensive review and 2016 update'Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia.Identification of novel small molecules that inhibit STAT3-dependent transcription and function.Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt.A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer.Novel STAT 3 inhibitors for treating gastric cancer.Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.The effects of signal transducer and activator of transcription three mutations on human platelets.Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug.Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome.Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors.A First-in-Human Phase 1 Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma.Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance

P2860

Q26746246-F6CD9CBC-01B5-4C2B-916B-DFD5DB4F5C9E Q26750725-14E8692E-A98E-48FD-88CF-332DCB2D7B9F Q28072539-E49A92E6-CBB2-4EE5-B669-B75535D0F3D3 Q33889046-67E68FC9-0277-4F3D-A432-6B745422B93F Q36411459-FDD1F221-101F-4C4F-A707-6A0C4BD692E5 Q38632603-F88E2CE7-DBE8-4D18-9676-1871F6BA45CA Q38764893-9CA16D4C-4052-44CF-A791-08BBEFAA6A9D Q38870465-542A5560-7A82-46E3-A233-3E3151EDA0B9 Q39057993-9909B6B7-C426-4AD4-88F7-F59AE9065F14 Q41993160-2CCB4E88-C479-4B3F-A097-E26A3A8ECEA9 Q47150116-C55FD01C-1627-4032-A76F-9CC6D68D5AB0 Q49262902-A7FA5E8F-FA85-49A0-9A91-41761DE2A695 Q49273540-7703AA9C-AF25-4DE6-839A-7D4019749878 Q49464971-A5AA1E5E-F380-4FEC-960A-F594113E0711 Q50191433-5958308A-092D-470E-95F3-246C281DB23F Q51825149-1B0A2EF0-CD28-4486-8BA9-0ADD9FDAAB62 Q52655071-158B7742-965D-4078-8C0A-FF13C8FFA81E Q52671159-4E6A14DD-2BE4-4A32-BA9F-7354B810D597 Q52687811-C0C5FBFF-A993-4B1F-A103-F172B84788E3 Q53610627-1E7FF2CF-CEBC-4A2B-A0CF-D21FAD9CAF53 Q58697165-C601BF2C-06BC-44E9-9C01-1C6BFEF4A598 Q58723081-02876461-7B6A-4BBD-A9C5-5E545EC22868 Q58729482-B4502F32-9DEB-4D70-B038-EDB265EDB9AD

P2860

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

http://www.wikidata.org/entity/Q36187003

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@ast

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@en

type

label

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@ast

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@en

prefLabel

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@ast

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@en

P1433

Q36187003-76CD5BFD-B5F8-4593-9386-562255A84C24

P1476

Q36187003-9AF4A7BB-20B5-4370-AF90-C0B12EA85169

P2093

Q36187003-1707D96E-43D3-4862-A7CD-FA0CB3F9CB3B

Q36187003-39FC6543-80D2-4F8B-815C-575BF08AC019

Q36187003-861547D8-2148-4069-ACCB-BF90247D0F91

Q36187003-A39D7A3F-89F6-4D20-A682-2DD7F17D7F52

Q36187003-A5987428-CEBD-4A42-840C-A8434C371E84

Q36187003-B9948212-414B-4C32-A50B-5B9300820938

Q36187003-D32C596F-2541-49B8-8B8C-AF6145881ED1

Q36187003-E1F2CF06-5FB7-4B10-A387-F01446B4614E

Q36187003-EA6EC025-E5D4-4B73-AF3C-F09C6EB19A73

Q36187003-FB87460E-04C1-4CE6-9FF3-47C5AB0A803D

P2860

Q36187003-0124DF12-E711-4090-8DBD-1E5B8906B112

Q36187003-0496C70F-AF26-4EE1-AAF5-772D16D666CF

Q36187003-0CFB476C-F74B-43E9-87C7-83581304CCA4

Q36187003-15757D33-3DD6-4814-86AE-B58D170FD8D4

Q36187003-280E76C0-1C0F-4726-BC9D-CEEA2F13F0B6

Q36187003-2F9CE1DB-8BDA-4CC5-B618-618E07246FCC

Q36187003-35CC65FF-60EA-463A-A958-1F9679032263

Q36187003-55EEE754-7012-45D3-935A-55F7A0702608

Q36187003-573C7621-DB53-4FA2-8A48-AE5795AEBFF5

Q36187003-585ED87D-30F7-4170-8454-E4778BA01291

P304

Q36187003-215AD43C-C9B0-4669-A1E0-C4548E968263

P31

Q36187003-C680427E-BDA9-4468-80F3-F686FB68CC69

P356

Q36187003-6C20F386-6823-4418-B3D8-13E9E160351A

P433

Q36187003-B1B07AE2-C9D6-457E-A862-BE2C6E22CB7C

P478

Q36187003-D5307471-9625-4B21-8376-2CEAE734765D

P577

Q36187003-329D1488-C00B-4813-9328-E373B740948E

P5875

Q36187003-ED1E7036-0B48-4F19-B261-34792CABB9F6

P698

Q36187003-69E3EB13-C5EA-4625-B94C-61A0E7C47F37

P932

Q36187003-902B0B42-F1F8-4F76-BB16-5BD65BB47218

P356

P1433

Cancer Research and Treatment

P1476

Phase I Study of OPB-31121, an ...... nts with Advanced Solid Tumors

@en

P2093

Dae Seog Heo

http://www.w3.org/2001/XMLSchema#string

Do-Youn Oh

http://www.w3.org/2001/XMLSchema#string

Mi-Jung Kim

http://www.w3.org/2001/XMLSchema#string

Miyuki Yuasa

http://www.w3.org/2001/XMLSchema#string

Sae-Won Han

http://www.w3.org/2001/XMLSchema#string

Se-Hoon Lee

http://www.w3.org/2001/XMLSchema#string

Tae-Min Kim

http://www.w3.org/2001/XMLSchema#string

Tae-You Kim

http://www.w3.org/2001/XMLSchema#string

Yasuo Yanagihara

http://www.w3.org/2001/XMLSchema#string

Yung-Jue Bang

http://www.w3.org/2001/XMLSchema#string

P2860

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

STATs in cancer inflammation and immunity: a leading role for STAT3

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

The STATs of cancer--new molecular targets come of age

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.

STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer

STAT3: a multifaceted oncogene.

P304

607-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4143/CRT.2014.249

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272838590

http://www.w3.org/2001/XMLSchema#string

P698

25715763

http://www.w3.org/2001/XMLSchema#string

P932

4614199

http://www.w3.org/2001/XMLSchema#string